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Abstract
Background: The aim of this study was to investigate the influence of body mass index (BMI) on the in vitro
fertilization (IVF) treatment outcomes in a cohort of women undergoing their first IVF, using an intracytoplasmic
sperm injection (ICSI).
Methods: This retrospective cohort study included 298 cycles from women younger than 38 years old undergoing
IVF-ICSI at a university infertility clinic. The treatment cycles were divided into three groups according to the BMI of
the women involved: normal weight (18.5≤ BMI < 25 kg/m2, 164 cycles), overweight (25≤ BMI < 30 kg/m2, 70 cycles),
and obese (BMI≥ 30 kg/m2, 64 cycles). The underweight women (BMI < 18.5 kg/m2) were not included in the analysis
due to small sample size (n = 22). The patient characteristics and IVF-ICSI treatment outcomes were compared between
the BMI groups.
Results: The total gonadotropin dose (p <0.001) and duration of stimulation (p = 0.008) were significantly higher in the
obese group when compared to the normal BMI group. There were no significant differences across the BMI categories
for the other IVF-ICSI cycle outcomes measured, including the number of retrieved oocytes, mature oocytes, embryos
suitable for transfer, proportion of oocytes fertilized, and cycle cancellation rates (p >0.05 for each). Additionally, clinical
pregnancy, spontaneous abortion, and the ongoing pregnancy rates per transfer were found to be comparable
between the normal weight, overweight, and obese women (p >0.05 for each).
Conclusion: Obese women might require a significantly higher dose of gonadotropins and longer stimulation
durations, without greatly affecting the pregnancy outcomes.
Background
Obesity has become a worldwide epidemic, with approxi-
mately 1.6 billion adults being overweight and 400 million
being obese [1]. Obesity has several serious consequences
on health, including hypertension, diabetes mellitus,
chronic heart disease, lipid disorders, uterine cancer, and
breast cancer [2, 3]. Moreover, obesity has negative effects
on reproductive health. It has been established that obesity
is associated with decreased natural fecundity, a decreased
ovulation rate, increased time until conception, and
increased rates of miscarriage [4, 5]. Additionally, an
increased rate of pregnancy complications, including
gestational hypertension, preeclampsia, gestational
diabetes, postpartum hemorrhage, and fetal macroso-
mia, are all associated with obesity [6, 7]. Since the in-
cidence of obesity is continually rising, an increasing
number of overweight and obese women are seeking
fertility treatments through assisted reproduction tech-
nology (ART) [8]. Consequently, there is a need to
understand the full impact of obesity on in vitro
fertilization (IVF) treatments.
There is conflicting evidence with regard to the effects
of a raised body mass index (BMI) on the outcome of
ART. Although some studies have reported no adverse
effects of a raised BMI on IVF outcomes [9, 10], others
have linked various negative impacts, including a higher
dose of gonadotropin stimulation, longer stimulation
duration, lower number of retrieved and mature oocytes,
and decreased embryo quality [4, 11]. The aim of this
study was to investigate the influence of BMI on the
* Correspondence: mozekinci@akdeniz.edu.tr
1Department of Obstetrics and Gynecology, Akdeniz University Faculty of
Medicine, 07059 Antalya, Turkey
Full list of author information is available at the end of the article
© 2015 Ozekinci et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ozekinci et al. BMC Women's Health  (2015) 15:61 
DOI 10.1186/s12905-015-0223-0
outcomes of ART in a cohort of women (≤38 years of
age) undergoing their first IVF-ICSI.
Methods
Between January of 2008 and October of 2013, a total of
1620 IVF-ICSI cycles were carried out at the infertility
clinic of the Gulhane Military Academy. Records of the
subjects following their first IVF-ICSI cycles were ana-
lyzed, and of these, 320 embryo transfer cycles fulfilled
our inclusion criteria: (i) women ≤ 38 years of age, (ii)
cycles arising from single embryo transfer (SET) or
double embryo transfer (DET), and (iii) where the data
on the outcome was available. Cycles arising from more
than two embryo transfers (ETs) and cryo-thaw embryos
were excluded from the analyses.
This study was approved by the institutional review
board of the Gulhane Military Academy (approval number
2013/168.4-2543). Since this was a retrospective cohort
study, no written informed consent for participation was
obtained from the participants. The patients underwent
IVF according to standard stimulation protocols, involving
pituitary down-regulation with either a GnRH agonist ad-
ministered in the mid-luteal phase of the prior cycle (long
protocol), or a diluted GnRH agonist given on days 2–4 of
the cycle (micro-dose protocol). Alternatively, a short
protocol with a GnRH antagonist was started when the
leading follicle reached 14 mm. Controlled ovarian stimu-
lation was achieved with hMG and/or recombinant FSH.
The response to stimulation was monitored using serum
E2 and a transvaginal ultrasound. Human chorionic go-
nadotropin (hCG) was administered to stimulate the final
stages of follicular development when the follicles reached
maturity, defined by two leading follicles over 18 mm. A
transvaginal follicle aspiration was performed 36 h after
hCG administration, and the embryo transfer took place
48 h later. Micronized vaginal progesterone, at daily dose
of 600 mg, was used for 2 weeks for luteal support.
The embryos were transferred to the uterus either
3 days (cleavage stage) or 5 days (blastocyst stage) after
the oocyte retrieval, and the embryo quality was assessed
on the day of transfer. The cleavage stage embryos were
scored based on cell number and the degree of fragmen-
tation, according to the grading system of Hardarson
(2001) [12]. The embryos at an appropriate developmen-
tal stage, with <20 % fragments and a mild degree of
uneven-sized blastomeres (grade I, grade IIA, and grade
IIB), constituted the day-3 embryos that were suitable
for transfer. In the case of extended culture, all of the
blastocyst stage embryos were evaluated using the grading
system of Gardner and Schoolcraft (1994). The blastocysts
were graded according to the degree of expansion, and the
quality of the inner cell mass and trophoectoderm [13].
The grade III–VI embryos, according to blastocyst expan-
sion and hatching status, with an inner cell mass and
trophoectoderm grades of A or B constituted the day-5
embryos suitable for transfer. The total number of em-
bryos suitable for ET (either at the cleavage or blastocyst
stage) was calculated for each patient.
At day 12 of the ET, each patient had her β-hCG levels
assessed. Pregnancy was defined by serially increasing
serum β-hCG titres to at least 25 IU/l, within 12 days
after the cleavage stage ET. All of the patients underwent
transvaginal ultrasounds at 5 to 6 weeks of gestation, or
when the β-hCG exceeded 2,000 IU/L, in order to deter-
mine the location and number of the pregnancies. Bio-
chemical pregnancy was defined as a transient pregnancy
that spontaneously resolved before the ultrasonographic
confirmation. Clinical pregnancy was documented by
ultrasonographic evidence of the fetal cardiac activity at
6–7 weeks of gestation. Spontaneous abortion was defined
as the loss of a clinical pregnancy. Additionally, ongoing
pregnancy was defined as progression beyond 12 weeks of
gestation.
The patients’ age, infertility duration-etiology, antral
follicle count, baseline FSH, LH, and estradiol levels
(cycle day 3) were reviewed. The IVF-ICSI cycle charac-
teristics, including the total gonadotropin dose used,
duration of stimulation, number of retrieved oocytes,
metaphase 2 (MII) oocytes, proportion of oocytes fertil-
ized, and embryo quality were noted. The women were
assessed for polycystic ovary syndrome (PCOS) as defined
by the 2003 Rotterdam European Society for Human
Reproduction and Embryology/American Society for
Reproductive Medicine sponsored PCOS consensus
workshop group [14]. The BMI was calculated by using
the formula weight/height2 from the medical records.
According to the World Health Organization (WHO)
guidelines, the women were grouped into three cat-
egories, namely normal: 18.5–24.9 kg/m2; overweight:
25–29.9 kg/m2; obese: ≥30 kg/m2. Because the number
of women in underweight group (BMI <18.5 kg/m2)
was low (n = 22), these patients were excluded from the
analysis.
The data were analyzed using the Microsoft Statistical
Package for the Social Sciences (SPSS) for Windows, ver-
sion 22.0. The Kruskal-Wallis test was conducted to ex-
plore the differences among the BMI categories, while the
Mann-Whitney U test was conducted to analyze the con-
tinuous and discrete ordinal variables, and the nominal data
was analyzed using the χ2 test. All of the Mann-Whitney U
and χ2 tests were two tailed, and Bonferroni’s correction
was used to adjust for multiple comparisons, unless other-
wise stated. The potential correlation between the BMI,
total gonadotropin dose, stimulation duration, and IVF-
ICSI treatment outcomes was evaluated using the
Spearman Rank Order Correlation. Finally, multiple re-
gression analyses were used to assess the variables for
the total gonadotropin dose and stimulation duration.
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Preliminary analyses were conducted to ensure no vio-
lation of the assumptions of normality, linearity, multi-
collinearity, and homoscedasticity. A P value of <0.05
was considered to be statistically significant.
Results
In total, 298 consecutive cycles (among 298 women)
with SET or DET were subjected to analysis. The mean
age at treatment was 30.4 years old (range 21–38), and
the clinical characteristics of the patients according to
the BMI categories are shown in Table 1. There were no
significant differences in the age and smoking status of the
women among the BMI categories. The duration of infer-
tility in years was significantly longer in the obese women,
when compared to the normal patients (p <0.001). How-
ever, the duration of infertility was found to be comparable
between the overweight and normal/obese patients. The
main cause of infertility was unexplained in 71 patients
(23.8 %), with the male factor in 67 (22.5 %), anovulation
in 31 (10.4 %), tubal factor in 63 (21.1 %), poor ovarian re-
serve in 12 (4.0 %), endometriosis in 12 (4.0 %), and com-
bined causes in 42 (14.1 %) patients. The distributions of
the etiologies were found to be similar between the BMI
categories. With regard to the clinical characteristics, there
were no significant differences in the total number of
antral follicles, polycystic ovaries upon ultrasound, PCOS,
or the baseline FSH, LH, and estradiol levels between the
groups.
Regarding the IVF-ICSI treatment outcomes, the total
gonadotropin dose (p <0.001) and duration of stimula-
tion (p = 0.008) were found to be significantly different
across the BMI categories. Subsequently, the total go-
nadotropin dose (p <0.001) and duration of stimulation
(p = 0.002) were significantly different between the nor-
mal and obese patients (Table 2, Fig. 1). However, the
gonadotropin dose and stimulation duration were found
to be comparable in the overweight and normal, and
overweight and obese patients. Additionally, there were
no significant differences between the BMI categories in
the number of retrieved oocytes, number of MII oocytes,
proportion of oocytes fertilized, number of embryos suit-
able for transfer, and number of canceled cycles. The
number of transferred embryos was found to be similar
between the BMI categories (SET was performed in
81.8 %, 79.4 %, and 78.0 % of the patients in the normal,
overweight, and obese patients, respectively). The percent-
age of blastocyst transfers was found to be comparable be-
tween the groups (embryo culture was extended in 34.6 %,
39.1 %, and 33.9 % of the patients in the normal, over-
weight, and obese patients, respectively). Finally, the
Table 1 Characteristics of the patients according to BMI
BMI
18.5–24.9 25.0–29.9 ≥30.0 P
(n = 164) (n = 70) (n = 64)
BMI (kg/m2) 21.9 ± 1.7a 27.1 ± 1.4b 33.1 ± 2.2c <0.001
Women’s age (yr) 30.1 ± 3.9 30.8 ± 3.8 30.8 ± 4.4 0.313
Years of infertility 4.1 ± 3.1a 4.7 ± 2.8a,b 5.7 ± 2.9b 0.002
Ever pregnant prior to inclusion 15 (9) 7 (10) 4 (8) 0.443
Smoking 44 (23.7) 18 (25.7) 13 (20.3) 0.106
Baseline FSH (pg/mL) 6.3 ± 1.7 6.2 ± 1.8 6.2 ± 1.6 0.550
Baseline LH (pg/mL) 6.1 ± 2.8 5.9 ± 1.8 4.8 ± 2.7 0.262
Baseline estradiol (pg/mL) 52.8 ± 26.6 50.7 ± 22.2 58.6 ± 27.1 0.193
Antral follicle count 10.7 ± 6.0 10.9 ± 6.6 12.4 ± 6.9 0.206
Polycystic ovaries on ultrasound 22 (13.4) 11 (15.7) 13 (20.3) 0.874
Polycystic ovary syndrome* 35 (26.9) 16 (29.1) 16 (31.4) 0.087
Unexplained infertility 41 (25.0) 16 (22.9) 14 (21.9) 0.657
Poor ovarian reserve 6 (3.7) 3 (4.3 %) 3 (4.7) 0.974
Male factor 38 (23.2) 16 (22.9) 13 (20.3) 0.858
Tubal Factor 34 (20.7) 16 (22.9) 13 (20.3) 0.692
Endometriosis 5 (3.0) 3 (4.3) 4 (6.3) 0.322
Anovulation 15 (9.1) 8 (11.4) 8 (12.5) 0.128
Combined infertility 25 (15.2) 8 (11.4) 9 (14.1) 0.332
Data are presented as mean ± standard deviation or n (%). BMI body mass index, ns non significant (p <0.05)
Values across a row with different superscripts (a-c) indicate significant difference between pregnancy outcome categories (p <0.017), and values across an
individual row with matching superscripts (a-c)indicate no significant difference between pregnancy outcome categories. *Excluding 62 cases (34 in normal-weight,
15 in overweight, and 13 in obese group) in which the complete data could not be obtained from the records available
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pregnancy outcomes, including the implantation rate, bio-
chemical, ectopic, clinical, and ongoing pregnancy, and
spontaneous abortion (per transfer) were found to be simi-
lar between the BMI categories.
The relationship between the BMI and IVF-ICSI treat-
ment outcomes was investigated using the Spearman
rank order correlation coefficient. There were positive
weak correlations between the BMI and the total go-
nadotropin dose (r = 0.27, p <0.001), and the duration of
stimulation (r = 0.20, p = 0.001). Additionally, there were
no statistically significant correlations between the BMI
and the number of retrieved oocytes, number of MII oo-
cytes, proportion of oocytes fertilized, number of em-
bryos suitable for transfer, spontaneous abortion, and
the ongoing pregnancy rates (p <0.05).
The multiple regression analysis was used to assess the
ability of the BMI to predict the total gonadotropin dose
and duration of stimulation (Table 3). The age, duration
of infertility, and presence of PCOS were added into the
same model, since they are potentially confounding fac-
tors. The prediction model was statistically significant
(p <0.001), and accounted for approximately 10 % of
the variance in the total gonadotropin dose (adjusted
R2 = 0.10). In the final model, the age (p = 0.001) and
BMI (p = 0.043) were found to be statistically significant
for predicting the total gonadotropin dose. The corre-
sponding adjusted R2 value for the prediction model of
the stimulation duration was 0.07 (p <0.001). In this
model, the BMI (p = 0.007) and PCOS (p = 0.008) were
found to be statistically significant.
Table 2 Characteristics of IVF-ICSI treatment according to body mass index (BMI)
BMI
18.5–24.9 25.0–29.9 ≥30.0 P
(n = 164) (n = 70) (n = 64)
Gonadotropin dose,
Total for cycle (IU) 1859 ± 1065a 2015 ± 968a,b 2455 ± 1343b <0.001
Per retrieved oocyte (IU) 256 ± 429 249 ± 336 249 ± 192 0.112
Per M2 oocyte (IU) 338 ± 557a 313 ± 358a 436 ± 434b 0.017
Per embryo suitable for transfer (IU) 785 ± 1039 661 ± 562 806 ± 749 0.087
Duration of stimulation (days) 8.7 ± 1.8a 8.9 ± 1.9a,b 9.8 ± 2.4b 0.008
Ovarian stimulation protocol
Long protocol 99 (60.4) 39 (55.7) 36 (56.2) 0.334
Short (antagonist) protocol 55 (33.5) 26 (37.2) 24 (37.5) 0.256
Micro dose protocol 10 (6.1) 5 (7.1) 4 (6.3) 0.134
No. of retrieved oocytes 12.3 ± 6.2 12.8 ± 6.1 13.2 ± 7.3 0.821
No. of MII oocytes 9.5 ± 5.3 9.2 ± 5.4 9.0 ± 6.9 0.329
Proportion of oocytes fertilized (%) 75.6 ± 20.1 79.1 ± 20.3 75.4 ± 22.1 0.215
No. of embryos suitable for transfer 4.2 ± 3.0 4.5 ± 3.3 3.6 ± 2.9 0.160
Extended culture 55 (34.6) 27 (39.1) 20 (33.9) 0.591
Canceled cycles 5 (3.0) 2 (2.9) 5 (7.8) 0.119
No. of transferred embryos SET 130 (81.8) 54 (79.4) 46 (78.0) 0.416
DET 29 (18.2) 14 (20.6) 13 (22.0)
Pregnancy outcome*
Implantation 62 (39.0) 26 (38.2) 21 (35.6) 0.755
Biochemical pregnancy 6 (3.8) 4 (5.8) 1 (1.7) 0.483
Ectopic pregnancy 2 (1.3) 0 (0.0) 1 (1.7) 0.595
Clinical pregnancy 52 (32.7) 22 (32.4) 18 (30.5) 0.953
Spontaneous abortion 6 (3.8) 3 (4.3) 3 (5.1) 0.909
Ongoing pregnancy 46 (28.9) 19 (27.9) 15 (25.4) 0.874
Data are presented as mean ± standard deviation or n (%). BMI body mass index, MII metaphase 2, SET single embryo transfer, DET double embryo transfer, ns non
significant (p <0.05)
Values across a row with different superscripts (a-b)indicate significant difference between pregnancy outcome categories (p <0.017), and values across an
individual row with matching superscripts (a-b)indicate no significant difference between pregnancy outcome categories. *Data for pregnancy outcomes are
expressed per embryo transfer
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Discussion
Higher gonadotropin consumption and longer stimula-
tion durations were observed in the obese females, when
compared with the normal weight women. However, we
did not find any significant differences in terms of em-
bryological parameters and cycle cancelation rates across
the BMI categories. Similarly, clinical pregnancy, spon-
taneous abortion and ongoing pregnancy rates were
found to be comparable between the groups.
The duration of infertility was significantly higher in
the obese women, when compared to the normal weight
women, although the mean age of the women between
the BMI categories was similar. Since it was the first
fresh cycle for each woman, this might indicate a pos-
sible delay in the infertility diagnosis or the lack of a
woman’s desire to seek treatment. We believe that mul-
tiple etiologies, including the concomitant health conse-
quences or psychological factors that are attributable to
obesity, might play a role in this issue.
In the current study, trends of higher gonadotropin
consumption and longer stimulation durations were
noted in the obese females, when compared with the
normal weight women. Similar to our results, a higher
dose of gonadotropin stimulation and a longer stimula-
tion duration were reported in the women with BMIs =
25–29.9 kg/m2, when compared with the women with
normal BMIs [15, 16]. Additionally, it was also shown
that a higher dose of gonadotropin stimulation and lon-
ger stimulation duration were required in women with
BMIs >30 kg/m2, when compared with women having
normal BMIs [15, 16]. Nevertheless, Farhi et al. reported
no statistically significant differences in the dose of go-
nadotropin stimulation in women with BMIs ≥25 kg/m2,
compared with women with BMIs <25 kg/m2 [17]. There-
fore, an increase in the gonadotropin dose and stimulation
duration might be more prominent in obese than over-
weight patients; however, the majority of studies in this
context do not discriminate isolated obesity from the pa-
tients with PCOS. Since PCOS is frequently associated
with an increased BMI, it might be essential to evaluate
those patients independently, in order to delineate the im-
pact of isolated obesity on IVF-ICSI outcomes. In order to
Fig. 1 Box-plots indicating total gonadotropin dose (IU) and duration of stimulation (days) among BMI categories. The medians and 25th-75th
percentiles are shown. Mann-Whitney U test was used for the analysis
Table 3 Multiple regression analysis of variables for total gonadotropin dose and duration of stimulation
Variable Multiple regression analysis
Gonadotropin dose, total for cycle (IU)a Duration of stimulation (days)b
β value P value β value P value
Age (years) 0.316 0.001 0.073 0.259
Years of infertility −0.025 0.707 0.044 0.498
BMI (kg/m2) 0.136 0.043 0.179 0.007
PCOS 0.029 0.663 0.178 0.008
BMI body mass index, PCOS polycystic ovary syndrome
aAdjusted R2 = 0.10
bAdjusted R2 = 0.07
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address this question, a multiple regression analysis was
performed, including both the BMI and PCOS. Similar to
our results, Loh et al. (2002) reported a significant increase
in the gonadotropin dose and duration of stimulation,
with BMIs >30 kg/m2 in non-PCOS patients [18].
With regard to the IVF-ICSI treatment outcomes, we
did not find any significant differences in the number of
retrieved oocytes, number of MII oocytes, proportion of
oocytes fertilized, embryo grades, and cycle cancelation
across the BMI categories. Currently, the literature lacks
consensus on the effects of obesity on IVF-ICSI treat-
ment outcomes. Although some studies have revealed a
lower number of oocytes retrieved in overweight and
obese women [10, 15], other studies were not able to
show such a difference in the number of oocytes re-
trieved among the different BMI groups [19–21]. An-
other concern is whether obesity affects oocyte maturity
or not. Dokras et al. have shown that the number of ma-
ture oocytes was significantly reduced in morbidly obese
women [20]; whereas, Metwally et al. have shown that
obesity did not have any significant effects on the oocyte
quality [22]. Studies have also assessed the impact of the
BMI on the fertilization rate. Matalliotakis et al. recently
found a significantly reduced fertilization rate in women
with BMIs of at least 24 kg/m2, when compared with
those with BMIs of less than 24 kg/m2 (58.9 vs. 51.7 %)
[10]. However, most of the other studies did not report a
significant difference in the fertilization rates between
the obese or overweight women and the normal women
[15, 20, 21]. Likewise, some studies have reported de-
creased embryo quality in obese and overweight women
[23], but the majority of studies, again, did not show any
significant effects with regard to this issue [24, 25]. Con-
sequently, there is largely conflicting evidence regarding
the effects of a raised BMI on the IVF-ICSI outcomes.
Rittenberg et al. recently conducted a meta-analysis in
order to explore the effects of the BMI on IVF treatment
outcomes [8]. They found significant reductions in the
clinical pregnancies and an increase in the miscarriage
rates in the women with BMIs of 25–29.9 kg/m2 and ≥30
kg/m2, when compared to the women with normal
BMIs. Although we observed a decreasing trend in the
clinical and ongoing pregnancy rates in the normal
through obese women, the differences did not reach
statistical significance in our study. Similarly, the spon-
taneous abortion rates were found to be comparable be-
tween the groups.
We analyzed only the first fresh ART cycle of every pa-
tient who met the inclusion criteria, to minimize the
confusing effects caused by the history of repeatedly
failed or cryo-preserved cycles. Additionally, in women
older than 38 years of age, which may specifically affect
the duration of ovarian stimulation, gonadotropin dose
and cancellation, and the implantation rates, were
excluded from the analyses. Despite these measures, our
study has several limitations, mainly due to its retro-
spective nature (e.g., missing data), as well as its rela-
tively small sample size and difficulty in controlling the
prior dose, type, and overall amount of gonadotropin ad-
ministered. The gonadotropin starting dose is usually
chosen according to the woman’s age, BMI, and markers
of ovarian reserve, including the antral follicle count.
However, we were unable to measure the anti-mullerian
hormone (AMH) levels at our institution, which might
complicate the evaluation of the association between the
total gonadotropin dose and the BMI. In addition, the
evaluation of the obesity in a cohort of patients, excluding
the poor responders, would be still appropriate. Further-
more, prospective investigations with a larger sample size
of obese patients (considering abdominal obesity, adipo-
kines and uterine environment) and more BMI cut-off
points might be necessary to intrinsically explore the ef-
fects of obesity on women’s reproduction potential with
regard to ART.
Conclusion
Our findings indicate that obese women might require
significantly higher doses of gonadotropins, and longer
stimulation durations, without greatly affecting the preg-
nancy outcomes.
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